This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
moving-average-crossover: Archive
Strength Seen in Cirrus Logic (CRUS): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
Cirrus Logic (CRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CRUSNegative Net Change ICHRPositive Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
PubMatic, Inc. (PUBM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
PUBMNegative Net Change
daily-movers moving-average-crossover stocks-moving-today
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MDGLPositive Net Change RIGLNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
KPTINegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Radcom (RDCM) Surges 8.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Radcom (RDCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
RDCMPositive Net Change CSCOPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
EchoStar (SATS) Moves 7.4% Higher: Will This Strength Last?
by Zacks Equity Research
EchoStar (SATS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
GSATNegative Net Change
momentum-stocks moving-average-crossover price-performance stock-price-movement stocks-moving-today
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
PROFNegative Net Change ACRSNegative Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Intuitive Machines, Inc. (LUNR) Surges 14.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Intuitive Machines, Inc. (LUNR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LUNRPositive Net Change HWMPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NRIXPositive Net Change QUREPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SRPTPositive Net Change CRBUPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today